In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From X-Chem, Inc.

Deal Watch: Merck Looks To Technology Platform Partners For Cytokine Agonist Discovery, Drug Delivery

Plus deals involving Moderna/Metagenomi, Agomab/Origo, Selecta/Ginkgo, Teva/MODAG, Boehringer Ingelheim/Thoeris and X-Chem/ComInnex/Glamorous AI.

Deal Watch Business Strategies

Finance Watch: $135m In Venture Capital Will Fund Amylyx’s Late-Stage ALS Drug

Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.

Financing Innovation

Deal Watch: Pfizer Invests In Spero, Parexel Trades Hands

EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.

Deal Watch Business Strategies

Deal Watch: Genentech Gets Access To X-Chem’s DNA-Encoded Library Technology

Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • ComInnex, Inc.
UsernamePublicRestriction

Register